Want to see IN:INDGN full AI Analyst Report?
Top Page
Indegene Limited
(INDGN)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹610.00
▲(23.80% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by solid financial performance—strong growth, healthy profitability, and a low-leverage balance sheet—tempered by volatile cash-flow conversion. Technicals add support with a clear positive trend and bullish momentum indicators. Valuation is the main offset, with a relatively high P/E and low dividend yield.
Positive Factors
Consistent revenue growth
Sustained top-line growth, including ~15% in 2026, indicates durable demand for Indegene's commercialization and medical services. Persistent revenue expansion supports scale, deeper client engagement and continued reinvestment in capabilities that underpin long-term competitiveness.
Negative Factors
Volatile cash-flow conversion
Material swings in operating cash flow and intermittent negative free cash flow years signal uneven cash conversion and earnings quality. This volatility complicates multi-quarter planning, increases reliance on working capital management, and raises execution risk for sustained investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained top-line growth, including ~15% in 2026, indicates durable demand for Indegene's commercialization and medical services. Persistent revenue expansion supports scale, deeper client engagement and continued reinvestment in capabilities that underpin long-term competitiveness.
Read all positive factors
Indegene Limited (INDGN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹124.07B
Dividend Yield0.44%
Average Volume (3M)17.62K
Price to Earnings (P/E)30.8
Beta (1Y)0.50
Revenue Growth30.41%
EPS Growth-8.20%
CountryIN
Employees4,687
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)16.73
Shares Outstanding240,954,300
10 Day Avg. Volume12,460
30 Day Avg. Volume17,622
Financial Highlights & Ratios
PEG Ratio-10.37
Price to Book (P/B)3.32
Price to Sales (P/S)2.97
P/FCF Ratio16.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.73
Revenue Forecast (FY)₹44.21B
Indegene Limited Business Overview & Revenue Model
Company Description
Operating globally with a strong presence in India, Indegene Limited functions as a specialized commercialization partner for the life sciences industry. It provides comprehensive support to biopharmaceutical, emerging biotech, and medical device ...
How the Company Makes Money
null...
Indegene Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
73
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.10B | 28.39B | 25.90B | 23.06B | 16.65B |
| Gross Profit | 35.10B | 28.39B | 25.90B | 23.06B | 16.65B |
| EBITDA | 6.19B | 6.42B | 5.81B | 4.54B | 2.65B |
| Net Income | 4.01B | 4.07B | 3.37B | 2.66B | 1.65B |
Balance Sheet | |||||
| Total Assets | 46.20B | 33.26B | 25.46B | 22.04B | 13.53B |
| Cash, Cash Equivalents and Short-Term Investments | 14.81B | 16.64B | 9.85B | 7.11B | 6.26B |
| Total Debt | 1.44B | 1.02B | 4.90B | 5.03B | 657.52M |
| Total Liabilities | 14.82B | 7.10B | 11.16B | 11.40B | 5.90B |
| Stockholders Equity | 31.39B | 26.16B | 14.29B | 10.64B | 7.64B |
Cash Flow | |||||
| Free Cash Flow | 6.19B | 4.12B | 4.97B | 1.11B | 2.72B |
| Operating Cash Flow | 6.63B | 4.42B | 5.08B | 1.30B | 2.97B |
| Investing Cash Flow | -5.25B | -6.83B | -3.27B | -8.93B | -1.60B |
| Financing Cash Flow | -826.00M | 2.88B | -662.00M | 3.33B | 2.33B |
Indegene Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹77.85B | 14.54 | ― | 2.00% | 13.21% | 12.05% | |
76 Outperform | ₹115.62B | 14.85 | ― | 2.49% | 8.06% | 15.25% | |
74 Outperform | ₹124.07B | 30.85 | ― | 0.41% | 30.41% | -8.20% | |
71 Outperform | ₹65.33B | 33.04 | ― | ― | 22.77% | 4.77% | |
67 Neutral | ₹84.55B | 14.78 | ― | 2.30% | 1.35% | 20.25% | |
65 Neutral | ₹94.20B | 24.74 | ― | 3.57% | 3.19% | -39.67% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:INDGN
Indegene Limited
554.10
-15.50
-2.72%
IN:BSOFT
Birlasoft Limited
318.75
-46.64
-12.77%
IN:CYIENT
Cyient Limited
857.30
-289.60
-25.25%
IN:LATENTVIEW
Latent View Analytics Limited
297.20
-91.55
-23.55%
IN:TANLA
Tanla Platforms Ltd
614.20
11.38
1.89%
IN:ZENSARTECH
Zensar Technologies Limited
499.00
-270.65
-35.17%
Indegene Limited Corporate Events
Indegene posts 39.7% YoY revenue surge and stronger margins in Q1 FY27
Jul 30, 2026
Indegene reported a strong start to FY27, with revenue from operations rising 39.7% year-on-year to ₹10,631 million (US$112.5 million) and 6.0% sequentially, marking its strongest first-quarter QoQ revenue growth in four years. The company&#...
Indegene Publishes Q1 FY27 Analyst Presentation and Fact Sheet
Jul 30, 2026
Indegene Limited has released an analyst presentation and fact sheet covering its financial results for the quarter ended June 30, 2026, in line with disclosure requirements under SEBI Listing Regulations. The materials, intended for investors and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.